The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
- C. Baigent, M. Landray, R. Collins
- Medicine, BiologyThe Lancet
- 9 June 2011
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
- B. Fellström, A. Jardine, F. Zannad
- MedicineNew England Journal of Medicine
- 2 April 2009
In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonf fatal myocardial infarction, or nonfatal stroke.
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
- H. Holdaas, B. Fellström, T. Pedersen
- MedicineThe Lancet
- 14 June 2003
Diagnostic Utility of Exome Sequencing for Kidney Disease
- E. Groopman, M. Marasà, A. Gharavi
- MedicineNew England Journal of Medicine
- 10 January 2019
Exome sequencing in a combined cohort of more than 3000 patients with chronic kidney disease yielded a genetic diagnosis in just under 10% of cases, with genetic findings for medically actionable disorders that would also lead to subspecialty referral and inform renal management.
Oxidative stress and endothelial function in chronic renal failure.
- M. Annuk, M. Zilmer, L. Lind, T. Linde, B. Fellström
- MedicineJournal of the American Society of Nephrology
- 1 December 2001
Results show that an impaired endothelium vasodilation function and oxidative stress are related to each other in patients with chronic renal failure.
Long‐term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study
- H. Holdaas, B. Fellström, A. Jardine
- MedicineAmerican Journal of Transplantation
- 1 December 2005
Fluvastatin produces a safe and effective reduction in LDL‐cholesterol associated with reduced risk of MACE in RTR, and the lipid‐lowering and cardiovascular benefits of fluvastatin are comparable to those of statins in other patient groups, and support use of fluVastatin in R TR.
Effects of lowering LDL cholesterol on progression of kidney disease.
- R. Haynes, D. Lewis, M. Landray
- Medicine, BiologyJournal of the American Society of Nephrology
- 1 May 2014
Lowering LDL cholesterol by 1 mmol/L did not slow kidney disease progression within 5 years in a wide range of patients with CKD and showed no significant effect on the rate of change in eGFR.
Impaired endothelium-dependent vasodilatation in renal failure in humans.
- M. Annuk, L. Lind, T. Linde, B. Fellström
- MedicineNephrology, Dialysis and Transplantation
- 1 February 2001
Patients with moderate CRF have an impaired EDV even after correction for traditional cardiovascular risk factors and this impairment is related to the degree of renal failure, according to this study.
INDUCTION OF B-TYPE RECEPTORS FOR PLATELET-DERIVED GROWTH FACTOR IN VASCULAR INFLAMMATION: POSSIBLE IMPLICATIONS FOR DEVELOPMENT OF VASCULAR PROLIFERATIVE LESIONS
- K. Rubin, G. Hansson, L. Terracio
- Biology, MedicineThe Lancet
- 18 June 1988
Ischemia causes rapidly progressive nephropathy in the diabetic rat.
- J. Melin, O. Hellberg, L. Akyürek, O. Källskog, E. Larsson, B. Fellström
- Medicine, BiologyKidney International
- 1 October 1997
It is concluded that in diabetic rats renal ischemia causes rapidly progressive kidney damage that in several respects resembles diabetic nephropathy in humans.
...
...